Loading...
XWAR
SLV
Market cap147mUSD
Jul 09, Last price  
30.45PLN
1D
1.00%
1Q
-6.88%
IPO
42.96%
Name

Selvita SA

Chart & Performance

D1W1MN
XWAR:SLV chart
P/E
687.34
P/S
1.53
EPS
0.04
Div Yield, %
Shrs. gr., 5y
1.29%
Rev. gr., 5y
21.55%
Revenues
364m
+6.57%
41,029,00048,133,00054,574,00070,679,00030,443,000137,356,000310,921,000360,680,000346,720,000342,007,000364,471,000
Net income
813k
P
6,270,0002,720,0003,926,00010,496,0005,523,00017,998,00014,899,00030,309,00069,878,000-6,098,000813,000
CFO
64m
+0.39%
-16,429,766-6,280,11210,538,65911,595,2824,299,16429,356,20387,472,02675,430,00078,980,00064,069,00064,319,999

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Selvita S.A., a contract research organization (CRO), provides its services across Poland, throughout Europe, in the United States, and to global clients. The company is structured around two main divisions: its core Contract Research Organization (CRO) offerings and Bioinformatics. Within its drug discovery portfolio, Selvita delivers a comprehensive suite of services including assay development and screening, expertise in medicinal and synthetic chemistry, advanced computer-aided drug design leveraging artificial intelligence, structural biology, in vitro and in vivo pharmacology studies, ADME/DMPK assessments, and general analytical testing. Furthermore, Selvita extends its capabilities to pharmaceutical services, encompassing drug testing and bioanalytical analysis. These services cover development and optimization processes, validation and transfer, stability studies, rigorous quality control, and assistance with regulatory compliance. The organization also engages in diverse research and development activities, such as process research, bespoke laboratory-scale synthesis of New Chemical Entities (NCEs), industrial chemistry solutions, and the creation of isotopically labeled compounds. Support for the agrochemical industry is also part of their R&D offerings. Moreover, Selvita delivers specialized bio-data science and sophisticated software solutions tailored for data-centric organizations within the life science and healthcare sectors. Established in 2007, Selvita S.A. maintains its headquarters in Krakow, Poland.
IPO date
Oct 16, 2019
Employees
847
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT